Role of immunomodulatory drugs in the treatment of lymphoid and myeloid malignancies
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F18%3A00012440" target="_blank" >RIV/00023736:_____/18:00012440 - isvavai.cz</a>
Result on the web
<a href="https://ebooks.benthamscience.com/book/9781681083674/" target="_blank" >https://ebooks.benthamscience.com/book/9781681083674/</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Role of immunomodulatory drugs in the treatment of lymphoid and myeloid malignancies
Original language description
Immunomodulatory drugs (IMiDs) or cereblon (CRBN) binding drugs such as thalidomide, lenalidomide and pomalidomide have similar structures and mechanism of action. Lenalidomide (CC5013, Revlimid®) was approved by the US FDA and the EMA for the treatment of multiple myeloma (MM) patients, low or intermediate-1 risk transfusion-dependent myelodysplastic syndrome (MDS) with chromosome 5q deletion [del(5q)] and relapsed and/or refractory mantle cell lymphoma following bortezomib. Lenalidomide has also been studied in clinical trials and has shown promising activity in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).
Czech name
—
Czech description
—
Classification
Type
C - Chapter in a specialist book
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Book/collection name
Frontiers in clinical drug research: hematology, vol. 3
ISBN
978-1-68108-368-1
Number of pages of the result
64
Pages from-to
73-137
Number of pages of the book
260
Publisher name
Bentham Science Publishers
Place of publication
Sharjah
UT code for WoS chapter
—